In The Lancet Infectious Diseases, Raquel González and colleagues1 report the results of a carefully conducted randomised placebo-controlled trial done in Gabon and Mozambique that assessed administration of monthly doses of dihydroartemisinin–piperaqu...
Chronic Chagas disease is caused by the protozoan Trypanosoma cruzi and affects around 6 million people in Latin America. Additionally, migration is favouring the spread of T cruzi infection throughout the world.1 After initial infection, about 60% of ...
Participants had a similar parasitological responses. However, reducing the usual treatment from 8 weeks to 2 weeks might maintain the same response while facilitating adherence and increasing treatment coverage. These findings should be confirmed in a...
The fexinidazole regimens in this study had an acceptable safety profile but did not prove effective against T cruzi infection. Development of fexinidazole monotherapy for treating T cruzi infection has been stopped.
De-escalation from an antipseudomonal β-lactam in Enterobacterales bacteraemia following a predefined rule was non-inferior to continuing the empiric antipseudomonal drug. These results support de-escalation in this setting.
De-escalation from an antipseudomonal β-lactam in Enterobacterales bacteraemia following a predefined rule was non-inferior to continuing the empiric antipseudomonal drug. These results support de-escalation in this setting.
In The Lancet Infectious Diseases, Luis Eduardo Lopéz Cortés and colleagues reported the results of the SIMPLIFY study, a multicentre, non-inferiority, open-label, randomised controlled trial investigating de-escalation of anti-pseudomonal β-lactams in...
In The Lancet Infectious Diseases, Luis Eduardo Lopéz Cortés and colleagues reported the results of the SIMPLIFY study, a multicentre, non-inferiority, open-label, randomised controlled trial investigating de-escalation of anti-pseudomonal β-lactams in...
Unsuccessful treatment of gonorrhoea has not yet occurred in the USA, and cases of gonorrhoea that are non-susceptible to cephalosporins have been rare. In 2019, non-susceptibility to ceftriaxone conferred by the mosaic penA 60.001 allele was found in ...
Unsuccessful treatment of gonorrhoea has not yet occurred in the USA, and cases of gonorrhoea that are non-susceptible to cephalosporins have been rare. In 2019, non-susceptibility to ceftriaxone conferred by the mosaic penA 60.001 allele was found in ...
The Lancet Infectious Diseases. A blueprint for elimination of cervical cancer. Lancet Infect Dis 2023; 24: 1—In this Editorial, the name of India's first domestic human papillomavirus vaccine should be Cervavac. This correction has been made to the on...
The Lancet Infectious Diseases. A blueprint for elimination of cervical cancer. Lancet Infect Dis 2023; 24: 1—In this Editorial, the name of India's first domestic human papillomavirus vaccine should be Cervavac. This correction has been made to the on...
To control infection with SARS-CoV-2 omicron XBB subvariants, the XBB.1.5 monovalent mRNA vaccine has been available since September, 2023. However, we have found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently indu...
Interim data report robust immune responses after vaccination with the monovalent XBB.1.5-adapted vaccines against XBB.1.5, and also against emerging SARS-CoV-2 sublineages, such as EG.5.1 and BA.2.86 in healthy individuals.1,2 However, patients on dia...
The efficacy of linezolid at a daily dose of 600 mg for 5 days did not meet the non-inferiority criteria compared with BPG and, as a result, this treatment regimen should not be used to treat patients with early syphilis.
In The Lancet Infectious Diseases, Maria Ubals and colleagues1 showed that linezolid 600 mg, taken orally once per day for 5 days was not effective in treating syphilis. Syphilis, a sexually transmitted disease caused by the bacterium Treponema pallidu...